Health Canada has approved Medicago’s COVID-19 vaccine, which uses GlaxoSmithKline’s adjuvant to increase its efficacy, making it the first approval of this plant-based vaccine worldwide.
The two-dose vaccine has been approved for people ages 18 to 64, the health agency said in a statement.
The vaccine was 75.3% effective against the delta variant of the coronavirus in a late-stage study, the two companies said in December.
The vaccine also showed an overall efficacy of 71% against all variants of the coronavirus except omicron, which was not in circulation at the time of the study.
The vaccine uses a technology known as virus-like particles, which mimic the structure of the coronavirus but do not contain its genetic material.
Canada has already licensed several vaccines, including those based on Moderna and Pfizer’s mRNA technology. Last week, it licensed the Novavax vaccine for use in adults.
Source: Gestion
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
